The effect of a GLP-1 agonist in patients with a dual diagnosis of Parkinson's Disease and Type 2 Diabetes Mellitus

Phase 4

Recruiting

• Conditions: Parkinson's Disease; Type 2 Diabetes Mellitus; Neurological - Parkinson's disease; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12620000627954
• Lead Sponsor: St Vincent's Health Network

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-29
• Last Update Posted: 2 November 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. Diagnosis of Parkinson’s disease meeting UK Brain Bank Criteria
2. Diagnosis of Type 2 Diabetes not receiving GLP-1 agonist therapy
3. HbA1c greater than or equal to 7 %
4. Willingness to give written informed consent and willingness to participate to and comply with the study.
5. Patients with cognitive impairment sufficient to impair capacity to provide informed consent are excluded from the study (MMSE<24)
6. Age >45 years

Exclusion Criteria

1. Patient incapable of providing informed consent
2. Patients receiving insulin treatment for type 2 diabetes
3. Contraindications to Extended release Exentatide (Bydureon) therapy including: pregnancy, Multiple Endocrine Neoplasia Type 2, Medullary Carcinoma of the thyroid, active Crohn’s disease or Ulcerative colitis, gastritis or severe gastroparesis, pancreatitis and chronic renal impairment with eGFR<30 ml/min

Study & Design

• Study Type: Interventional
• Study Design: Not specified